Cortice Biosciences Announces Enrollment Of A Phase 1 Clinical Trial Evaluating TPI 287 In Rare Tauopathy Diseases
7/7/2014 8:21:11 AM
NEW YORK, July 7, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that enrollment has begun in a Phase 1 trial designed to evaluate safety, tolerability and preliminary efficacy of the company's lead drug candidate, TPI 287, for treatment of patients with progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) (clinicaltrials.gov/NCT02133846). PSP and CBD represent diseases of the central nervous system collectively known as tauopathies, and for which no FDA approved therapies exist. This trial is being led by investigators at the University of California San Francisco (UCSF), and with generous support from CBD Solutions, a non-profit organization dedicated to finding a cure for CBD.
Help employers find you! Check out all the jobs and post your resume.
comments powered by